Joining Alphabet precision health firm â€œat this inflection point is incredibly compelling,â€ says Indian American executive
Indian American executive Utpal Koppikar with a distinguished career in finance in the life sciences industry, has been named Chief Financial Officer of Verily, an Alphabet company focused on precision health.
Koppikarâ€™s appointment follows the announcement of a refined strategy and product portfolio in late January, according to a company press release. Last September, Verily raised $1 billion in an investment round led by Alphabet.
Read: Priti Krishtel named to global anti-racist health panel (February 16, 2023)
â€œUtpal brings to Verily deep financial expertise as well as decades of experience in the life sciences industry at some of the most innovative companies in the sector,â€ said Stephen Gillett, Chief Executive Officer of Verily.
â€œWeâ€™re thrilled to have his financial and life sciences acumen as we accelerate our path to sustainable, long-term growth with increasingly connected solutions that close the gap between research and care and further our precision health strategy.â€
â€œThe opportunity to join Verily at this inflection point is incredibly compelling as Stephen and the leadership team have the vision and determination to make precision health commercially successful,â€ said Koppikar.
â€œAt this significant juncture, the company has the commitment of investors and the capital to invest in research, care and precision risk management to potentially transform the lives of patients.â€
Koppikar joins Verily from Atara Biotherapeutics, a leader in T-cell immunotherapy focused on cancer and autoimmune diseases, where he was Executive Vice President and Chief Financial Officer and where he oversaw the finance, information technology and investor relations functions, according to a press release.
Prior to Atara, Koppikar held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance.
During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gileadâ€™s Vice President of Finance for Europe, the Middle East and Australia.
Before joining Gilead, Koppikar served in multiple finance roles of increasing responsibility at Amgen. He serves on the board of C4 Therapeutics and was previously a board member of Flexion Therapeutics Inc, until its sale to Pacira Biosciences Inc.
Verily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered, according to the release. Launched from X in 2015, Verilyâ€™s purpose is to bring the promise of precision health to everyone, every day.